Skip to content

Clinical study for adjuvant radiotherapy of stage II/III distal rectal cancer patients following transanal total mesorectal excision

Clinical study for adjuvant radiotherapy of stage II/III distal rectal cancer patients following transanal total mesorectal excision

Status
Active, not recruiting
Phases
Phase 2
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900022358
Enrollment
Unknown
Registered
2019-04-07
Start date
2019-04-15
Completion date
Unknown
Last updated
2019-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rectal cancer

Interventions

Case series:adjuvant radiotherapy

Sponsors

Department of oncology Second Affiliated Hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. histologically proven malignant tumor of rectal; stage II-III (exclude T4) received transanal total mesorectal excision; 2. Life expectancy 3 months or longer; 3. KPS score =70; 4. Adequate hematologic and end organ function, defined by the following laboratory results obtained within 7 days prior to randomization: Hemoglobin = 100g/L, ANC = 1.5*10^9/L without granulocyte colony-stimulating factor support, Platelet count =100*10^9/L; Serum bilirubin = 1.5×ULN, AST, ALT = 1.5×ULN; Serum creatinine = 1.5 × ULN or eGFR =60ml/min, urea nitrogen =200mg/L; 5. Women who are not postmenopausal or surgically sterile must have a negative serum pregnancy test result within 7 days prior to initiation of study. For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception and to continue its use for 180 days after the last radiation; 6. Signed Informed Consent Form; 7. Comply with research plan and follow-up process; 8. Male or female aged 18 to 75 years.

Exclusion criteria

Exclusion criteria: 1. Recurrent patients of rectal carcinoma; 2. Received neoadjuvant radiotherapy for rectal carcinoma; 3. Treatment with any other investigational agent or participation in another clinical trial; 4. Malignancies other than rectal carcinoma within 5 years; 5. History of any systemic diseases including: active infections, uncontrolled hypertension, congestive heart-failure, myocardial infarction, severe arrhythmia, liver, kidney or metabolic diseases; 6. Positive test for HIV; 7. Any other condition that contraindicates the use of radiation or that may affect the interpretation of the results or render the patient at high risk from treatment complications.

Design outcomes

Primary

MeasureTime frame
toxicity;quality of life;recurrence free survival;

Secondary

MeasureTime frame
Overall survival;Progression-Free-Survival;

Contacts

Public ContactAnmei Zhang

Department of oncology Second Affiliated Hospital of Army Medical University

8015003@qq.com+86 13637915856

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026